# Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients

> **NCT05237726** · NA · COMPLETED · sponsor: **King Abdullah International Medical Research Center** · enrollment: 20 (actual)

## Conditions studied

- Burns

## Interventions

- **DRUG:** Enoxaparin 40 mg q24 hours
- **DRUG:** Enoxaparin 30 mg q12 hours
- **DRUG:** Unfractionated heparin 5000 U q8 hours

## Key facts

- **NCT ID:** NCT05237726
- **Lead sponsor:** King Abdullah International Medical Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-05
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05237726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05237726, "Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05237726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*